Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Developmental and/or Epileptic Encephalopathies
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Phoenix, Arizona • Port Charlotte, Florida • Tampa, Florida + 8 more

Conditions: Hiv, Fatigue, Mobility Limitation
Interventions: HIIT (intervention), CME (active control), Coaching, Control text message; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Healthy
Interventions: ADX48621, [18F]FPEB; Drug · Radiation
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pharmacokinetics, Safety, Food-drug Interaction
Interventions: 200 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL, 700 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL administered to assess influence of food; Drug
Lead sponsor: Jupiter Orphan Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Sarcoma, Bone, Sarcoma, Soft Tissue, Gait Disorder
Interventions: Lab based 3D Gait Assessment, Wearable Inertial Sensors (In Lab and Remote), Functional Testing & Patient Reported Outcomes, Remote Wearable Sensor Assessment; Diagnostic Test · Device · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 20 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cholestasis, Total Parenteral Nutrition-induced Cholestasis
Interventions: Omegaven; Drug
Lead sponsor: Cindy Haller; Other
Eligibility: 2 Weeks to 5 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Manhasset, New York • New Hyde Park, New York

Conditions: Human Immunodeficiency Virus
Interventions: 3BNC117, 10-1074, Analytical treatment interruption; Drug · Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Prostate Cancer, Cardiovascular Disease
Interventions: Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor; Behavioral · Drug
Lead sponsor: McMaster University; Other
Eligibility: 45 Years and older · Male only
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 4
States / cities: Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more

Conditions: Pseudoxanthoma Elasticum
Interventions: Magnesium Oxide, Placebo; Drug
Lead sponsor: Mark Lebwohl; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Posttraumatic Stress Disorder
Interventions: Not listed
Lead sponsor: RTI International; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Honolulu, Hawaii • Fort Bragg, North Carolina

Conditions: Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions: alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS; Drug · Biological · Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: FPI-2265; Drug
Lead sponsor: Fusion Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 18
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 12 more

Conditions: Infant Behavior, Infant Development, Self-Control, Self-Regulation, Emotion
Interventions: Early Self-Regulation Intervention; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Months to 18 Months
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Volunteers
Interventions: IP, Matching Placebo; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Fibromyalgia
Interventions: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation; Device
Lead sponsor: Charles (Chuck) Raison; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: BRCA1/2 Mutation
Interventions: INO-5401, INO-9012, Cellectra 2000; Drug · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Osteochondral Defect
Interventions: osteochondral transplant on the femoral condyle; Procedure
Lead sponsor: AlloSource; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 6
States / cities: Phoenix, Arizona • Los Angeles, California • Redwood City, California + 3 more

Conditions: Prostate Cancer
Interventions: Questionaires, fMRI scan (optional); Behavioral · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 2
States / cities: Duarte, California • New York, New York

Conditions: Healthy Volunteers
Interventions: TS-142, TS-142 Placebo; Drug
Lead sponsor: Taisho Pharmaceutical R&D Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Autism Spectrum Disorder
Interventions: Autism Pupil Screen (APS) Detect PLR Assessment #1, Modified Checklist for Autism in Toddlers, Revised with Follow-up (M-CHAT/R-F), Social Responsiveness Scale, Second Edition (SRS-2), Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), Mullen Scales of Early Learning (MSEL), Adaptive Behavior Assessment System, Third Edition (ABAS-3), Autism Pupil Screen (APS) Detect PLR Assessment #2, Autism Pupil Screen (APS) Detect Assessment #3, Well-child check; Device · Other · Diagnostic Test + 1 more
Lead sponsor: Schweitzer Engineering Laboratories; Industry
Eligibility: 24 Months to 60 Months
Enrollment: 330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Lewiston, Idaho • Moscow, Idaho • Pullman, Washington

Conditions: Diabetes Mellitus, Type 1
Interventions: EMR-based BPA model, Placebo (EMR-based without BPA model); Other · Behavioral
Lead sponsor: T1D Exchange, United States; Other
Eligibility: 2 Years to 95 Years
Enrollment: 1,178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Advanced Solid Tumours
Interventions: AZD1775, MEDI4736; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 3
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee

Conditions: Colon Polyps, Colorectal Cancer, Inflammatory Bowel Disease (IBD)
Interventions: Colon KCC Heptapeptide; Biological
Lead sponsor: Danielle Kim Turgeon; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration

JOTROL PK, Safety, and Food Effect Assessment

Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients

Compassionate Use of Omegaven IV Fat Emulsion

3BNC117 and 10-1074 in ART-treated Individuals

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Acceptability

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Pilot Study: A Telehealth Intervention for Caregivers of Infants With Early Signs of ADHD

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

Whole Body Hyperthermia (WBH) as a Rapid Treatment for Fibromyalgia

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Evaluating Cryopreserved Osteochondral Allograft Cores for the Treatment of Osteochondral Lesions in the Knee

The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants

A Drug Interaction Study of LY3871801 in Healthy Participants

Effectiveness of the Autism Pupil Screen (APS) Detect Pupillometer for Identifying Autism Spectrum Disorder (ASD) in Routine Healthcare

Best Practice Advisories to Reduce Inequities in Technology Use for People With Type 1 Diabetes

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Study of KCC Peptide Application in the Colon